A detailed history of Prelude Capital Management, LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Prelude Capital Management, LLC holds 4,730 shares of ASND stock, worth $684,052. This represents 0.05% of its overall portfolio holdings.

Number of Shares
4,730
Holding current value
$684,052
% of portfolio
0.05%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$121.07 - $153.67 $572,661 - $726,859
4,730 New
4,730 $645,000
Q4 2023

Feb 14, 2024

SELL
$86.1 - $127.36 $60,269 - $89,152
-700 Reduced 9.72%
6,500 $818,000
Q3 2023

Nov 14, 2023

BUY
$86.5 - $103.97 $69,200 - $83,176
800 Added 12.5%
7,200 $674,000
Q2 2023

Aug 14, 2023

SELL
$69.96 - $97.84 $111,935 - $156,544
-1,600 Reduced 20.0%
6,400 $571,000
Q1 2023

May 15, 2023

BUY
$104.9 - $126.78 $73,430 - $88,746
700 Added 9.59%
8,000 $857,000
Q4 2022

Feb 14, 2023

BUY
$99.42 - $131.97 $228,666 - $303,531
2,300 Added 46.0%
7,300 $891,000
Q3 2022

Nov 14, 2022

SELL
$84.03 - $110.23 $84 - $110
-1 Reduced 0.02%
5,000 $516,000
Q2 2022

Aug 15, 2022

BUY
$78.08 - $117.61 $210,894 - $317,664
2,701 Added 117.43%
5,001 $465,000
Q1 2022

May 16, 2022

SELL
$102.18 - $135.75 $275,886 - $366,525
-2,700 Reduced 54.0%
2,300 $270,000
Q4 2021

Feb 14, 2022

BUY
$127.1 - $169.66 $380,791 - $508,301
2,996 Added 149.5%
5,000 $673,000
Q3 2021

Nov 15, 2021

BUY
$112.67 - $176.92 $450 - $707
4 Added 0.2%
2,004 $319,000
Q2 2021

Aug 16, 2021

BUY
$121.62 - $145.29 $243,240 - $290,580
2,000 New
2,000 $263,000
Q4 2020

Feb 16, 2021

SELL
$151.2 - $182.76 $505,007 - $610,418
-3,340 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$134.29 - $154.32 $448,528 - $515,428
3,340 New
3,340 $515,000

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $8.07B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.